Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course bortezomib in refractory cold agglutinin disease with anemia
2011-006329-42Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Oct 2012
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in cold agglutinin disease (CAD) and Hemolytic anemia (HA), sponsored by GIMEMA. Primary endpoint: Transfusion independence or hemoglobin response at 3 months. Started Oct 2012; status: completed.
02
Drugs
bortezomib
03
Conditions
cold agglutinin disease (CAD)Hemolytic anemia (HA)
Beyond the preview
Go deeper on 2011-006329-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006329-42.